Theralase Technologies (CVE:TLT) Stock Price Down 5% - Should You Sell?

Key Points

• Shares fell about 5% to C$0.29 mid‑day, with 63,007 shares traded—down 71% from the average session volume of 213,608, after a prior close of C$0.30.
• The company has a market cap of C$75.79 million and a negative P/E of -15.28, with a 50‑day moving average of C$0.29 and a 200‑day moving average of C$0.24.
• Theralase is a clinical‑stage pharmaceutical developer of light‑activated photo dynamic compounds for cancers, bacteria and viruses, and also markets patented super‑pulsed laser devices for pain and tissue healing.

Theralase Technologies Inc. (CVE:TLT - ) shares traded down 5% during mid-day trading on Tuesday . The stock traded as low as C$0.29 and last traded at C$0.29. 63,007 shares changed hands during mid-day trading, a decline of 71% from the average session volume of 213,608 shares. The stock had previously closed at C$0.30.

Theralase Technologies Stock Performance

The company has a 50 day moving average price of C$0.29 and a 200-day moving average price of C$0.24. The company has a current ratio of 0.83, a quick ratio of 3.40 and a debt-to-equity ratio of 29.26. The company has a market cap of C$75.79 million, a P/E ratio of -15.28 and a beta of -0.31.

Theralase Technologies Company Profile

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.